redosing

redosing

(rē″dōs′ing)
Administration of an additional dose of a medication.
redose
References in periodicals archive ?
A detailed discussion on development of Abeonas proprietary AIM vector system, a next generation platform of AAV capsids being developed in collaboration with the University of North Carolina at Chapel Hill; initial studies indicate that AIM vectors can efficiently target multiple tissues with vector-selective tissue specificity with different routes of administration relative to first generation vectors, providing second-generation treatment approaches for patients as a redosing strategy or for patients that have neutralizing antibodies to natural AAV serotypes.
Additionally, follow-up to address sustainability and redosing of education would enhance staff nurse confidence and promote optimal patient outcomes.
Also included was antibiotic redosing at 3 hours and intraoperative maintenance of temperature above 36[degrees] C.
293, 298-301 (2013) (noting that emergency providers with the highest patient volumes have the most negative attitudes toward patients with sickle cell and are the least likely to follow practice guidelines of redosing patients with opioids).
We do not recommend redosing the 4-factor PCC, nor do we recommend providing rFVIIa or FEIBA within 24 hours of a dose of the 4-factor PCC owing to our concern for possible thromboembolic complications.
It warned users were continually redosing the drug intravenously.
Intraoperative redosing of cefazolin and risk for surgical site infection in cardiac surgery.
Timing and frequency of physostigmine redosing for antimuscarinic toxicity.
inappropriately redosing antibiotics at minute 61 without apparent clinical indication purely for the sake of SCIP-1 compliance).
Rats given the therapy carried on producing a protein nourishing dopamine for long periods, avoiding the need for redosing.
27 January 2012 - Cornerstone Therapeutics (NASDAQ:CRTX), a specialty pharmaceutical group focused on products for respiratory conditions, said that a new analysis revealed significant benefits in mortality rate and the need for redosing in the treatment of neonatal respiratory distress syndrome (RDS) with the company's CUROSURF (poractant alfa) Intratracheal Suspension.